The effect of quercetin supplement on patients with myocardial infarctio

Phase 3

Conditions: myocardial infarction.
ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction

Registration Number: IRCT20090822002365N19

Lead Sponsor: Iran University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 88

Inclusion Criteria

Having the consent and willingness to participate in the study
Age range from 35 to 65 years
Passing 6 to 8 weeks after the first heart attack
BMI< 30 Kg/m2

Exclusion Criteria

Smoking, alcohol consumption or narcotic use
Taking vitamin, antioxidant or omega-3 supplements in the last 3 months
Taking non-steroidal anti-inflammatory drugs over the past 3 months
Suffering or having a history of chronic inflammation, kidney, liver and thyroid disease
The occurrence of any problem or sensitivity at any time during the study
Non-compliance with treatment (less than 80% or less than 48 days)
Changes in physical activity, diet, or change in the type and dosage of the drug during the study and the occurrence of acute illness

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Tumor necrosis factor alpha (TNF-a). Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: The level of TNF-a in serum is with ELISA method.;High-sensitive C-reactive protein (hs-CRP). Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: The level of hs-CRP in serum with Immunoturbidimetry method.

Secondary Outcome Measures